Effective half-lives for patients administered radiolabeled antibodies and calculated dose to the public in close proximity to patients

Health Physics

Volumn 78, Issue 2, 2000, Pages 215-221

  Kaurin, D G L ^a,b   Carsten, A L ^b   Baum, J W ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Effective dose; Exposure, population; Medical radiation; Radiopharmaceuticals

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLEARANCE; DOSE CALCULATION; FEMALE; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION EXPOSURE;

EID: 0033979923     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004032-200002000-00010     Document Type: Article

References (12)

1. Barber, D. E.; Baum, J. W.; Meinhold, C. B. Radiation safety issues related to radio-labeled antibodies. Washington, DC: U.S. Nuclear Regulatory Commission; NUREG/CR-4444, BNL-NUREG-52275; 1991.
2. Bevington, P. R. Data reduction and error analysis of the physical sciences. New York: McGraw-Hill, Inc.; 1969.
3. 131I Lym-1 monoclonal antibody. Antibody, Immunoconjugates, and Radiopharm. 1:17-33; 1988.
4. 2 fragments of monoclonal antibody in humans. Med. Phys. 11:778-783; 1984.
5. Harbert, J. C.; Wells, N. Radiation exposure to the family of radioactive patients. J. Nucl. Med. 15:887-888; 1974.
6. Jacobson, A. P.; Plato, P. A.; Toeroek, D. Contamination of the home environment by patients treated with iodine-131: Initial results. American J. Public Health 68:225-230; 1978.
7. Kaurin, D. G. L.; Barber, D. E.; Garsten, A. L.; Baum, J. W. Whole-body effective half-lives for radiolabeled antibodies and related issues. Washington, DC: U.S. Nuclear Regulatory Commission; NUREG/CR-6374, BNL-NUREG-52476; 1996.
8. Leichner, P. K.; Klein, J. L.; Siegelman, S. S.; Ettinger, D. S.; Order, S. E. Dosimetry of 131-I-labeled antiferritin in hepatoma: specific activities in the tumor and liver. Cancer Treatment Reports 67:647-658; 1983.
9. Meredith, R. F.; LoBuglio, A. F.; Plott, W. E.; Orr, R. A.; Brezovich, I. A.; Russell, C. D.; Harvey, E. B.; Tester, M. V.; Wagner, A. J.; Spencer, S. A.; Wheeler, R. H.; Saleh, M. N.; Rogers, K. J.; Polansky, A.; Salter, M. M.; Khazaeli, M. B. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, k 17-1A monoclonal antibody. J. Nucl. Med. 32:1162-1168; 1991.
10. SAS Institute, Inc. SAS/STAT® User's Guide, Version 6. Fourth edition, Vols. 1 and 2. Gary, NC: SAS Institute; 1989.
11. U.S. Nuclear Regulatory Commission. Criteria for the release of individuals administered radioactive material. Federal Register 62:4120-4133; 1997a.
12. U.S. Nuclear Regulatory Commission. Release of patients administered radioactive materials. Regulatory Guide 8.39. Washington DC: U.S. Nuclear Regulatory Commission, Office of Nuclear Regulatory Research; 1997b.